Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Pruritus

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    479 result(s) found for: Pruritus. Displaying page 1 of 24.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2013-002763-25 Sponsor Protocol Number: NT2013/Orv/Prot001 Start Date*: 2013-10-11
    Sponsor Name:NeRRe Therapeutics Ltd
    Full Title: A randomised, double-blind, placebo-controlled study to evaluate the efficacy of two different dose levels of orvepitant (10 and 30 mg) compared with placebo on EGFRi-induced intense pruritus in on...
    Medical condition: Intense pruritus, in oncology subjects, induced by EGFRi
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004858 10023084 Itching LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-015090-12 Sponsor Protocol Number: 04082009 Start Date*: 2013-07-23
    Sponsor Name:Association of Dutch Burn Centres
    Full Title: Standard Treatment Or topical doxepin against Pruritus in burn patients
    Medical condition: Pruritus in patients with burns
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004863 10006799 Burns NOS LLT
    16.0 100000004858 10037090 Pruritus cutaneous LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-000610-26 Sponsor Protocol Number: MK-4117-202 Start Date*: 2017-02-09
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III, Multicenter, Open-Label Long-Term Trial to Study the Efficacy and Safety of MK-4117 in Japanese Subjects With Eczema/Dermatitis and Dermal Pruritus.
    Medical condition: Eczema/dermatitis and the dermal pruritus (itchy skin disease)
    Disease: Version SOC Term Classification Code Term Level
    19.1 10040785 - Skin and subcutaneous tissue disorders 10012431 Dermatitis PT
    19.1 10040785 - Skin and subcutaneous tissue disorders 10014184 Eczema PT
    19.1 10040785 - Skin and subcutaneous tissue disorders 10037090 Pruritus cutaneous LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-002931-25 Sponsor Protocol Number: VP-VLY-686-2101 Start Date*: 2013-11-05
    Sponsor Name:Vanda Pharmaceuticals Inc.
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF OF CONCEPT, ANTIPRURITIC STUDY OF THE NEUROKININ-1 RECEPTOR ANTAGONIST VLY-686 IN SUBJECTS WITH TREATMENT-RESISTANT PRURITUS ASSOCIATED WITH AT...
    Medical condition: Males or females with treatment resistant pruritus associated with atopic dermatitis.
    Disease: Version SOC Term Classification Code Term Level
    17.1 10040785 - Skin and subcutaneous tissue disorders 10037087 Pruritus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-007815-99 Sponsor Protocol Number: AN07/8429 Start Date*: 2009-03-09
    Sponsor Name:Leeds Teaching Hospitals NHS Trust
    Full Title: The optimal dose of subcutaneous naloxone for the treatment of intrathecal opioid- induced pruritus following elective caesarean section delivery
    Medical condition: Pruritus secondary to intrathecal opioids
    Disease: Version SOC Term Classification Code Term Level
    9.1 10049981 Drug-induced pruritus LLT
    Population Age: Adults Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2021-004315-76 Sponsor Protocol Number: EFC16973 Start Date*: 2022-01-13
    Sponsor Name:SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
    Full Title: Master protocol of two randomized, double blind, placebo-controlled, multicenter, parallel group studies to evaluate the efficacy and safety of dupilumab in adult patients with chronic pruritus of ...
    Medical condition: Chronic pruritus of unknown origin (CPUO)
    Disease: Version SOC Term Classification Code Term Level
    24.1 10040785 - Skin and subcutaneous tissue disorders 10037087 Pruritus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing) ES (Ongoing) HU (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-004794-33 Sponsor Protocol Number: PA101B-UP-02 Start Date*: 2016-03-25
    Sponsor Name:Patara Pharma, LLC
    Full Title: Treatment of Uremic Pruritus with Inhaled PA101B in Patients with End-Stage Renal Disease Requiring Hemodialysis
    Medical condition: Uremic Pruritus in patients with end-stage renal disease requiring hemodialysis
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004858 10060884 Uremic pruritus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000481-32 Sponsor Protocol Number: THYPOS Start Date*: 2016-05-03
    Sponsor Name:UNIVERSITÀ CAMPUS BIO-MEDICO DI ROMA
    Full Title: TERIPARATIDE FOR THE PRIMARY PREVENTION OF POST-SURGICAL HYPOCALCEMIA
    Medical condition: POST SURGICAL HYPOCALCEMIA
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10033557 Palpitations PT
    20.0 10047065 - Vascular disorders 10021097 Hypotension PT
    20.0 10040785 - Skin and subcutaneous tissue disorders 10037087 Pruritus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-004766-35 Sponsor Protocol Number: RD.06.SPR.204358 Start Date*: 2022-06-06
    Sponsor Name:Galderma S.A.
    Full Title: A Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Nemolizumab in Subjects with Chronic Kidney Disease with Associated Severe Pruritus
    Medical condition: Chronic Kidney Disease Associated Severe Pruritus
    Disease: Version SOC Term Classification Code Term Level
    24.1 10040785 - Skin and subcutaneous tissue disorders 10037087 Pruritus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) HU (Ongoing) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-002482-15 Sponsor Protocol Number: M23-696 Start Date*: 2022-12-27
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG (AbbVie)
    Full Title: A Phase 3b/4 Randomized, Open-label, Efficacy Assessor Blinded Study, Comparing the Safety and Assessor Blinded Efficacy of Upadacitinib to Dupilumab in Subjects with Moderate to Severe Atopic Derm...
    Medical condition: Moderate to Severe Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10012438 Dermatitis atopic PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Ongoing) HU (Ongoing) SK (Completed) SE (Completed) FR (Completed) PL (Ongoing) IT (Ongoing) PT (Ongoing) DK (Completed) NL (Ongoing) GR (Ongoing) BE (Ongoing) BG (Ongoing) HR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-002416-41 Sponsor Protocol Number: 201000 Start Date*: 2017-02-17
    Sponsor Name:GlaxoSmithKline, S.A.
    Full Title: A randomized, double-blind, multi-dose, placebo-controlled study to evaluate the efficacy, safety and tolerability of GSK2330672 administration for the treatment of pruritus in patients with primar...
    Medical condition: Primary biliary cholangitis (PBC)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10019805 - Hepatobiliary disorders 10008604 Cholangitis PT
    19.0 10040785 - Skin and subcutaneous tissue disorders 10037087 Pruritus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GB (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-001601-85 Sponsor Protocol Number: UKM10_0037 Start Date*: 2014-02-14
    Sponsor Name:University Hospital Münster
    Full Title: Aprepitant in histamine-refractory chronic pruritus: a multicenter, randomized, double-blind, placebo-controlled, cross-over, phase II trial
    Medical condition: Patients with generalized chronic pruritus (> 6 weeks duration) and showing prurigo nodularis refractory to pretreatment with antihistamines (normal dosage, four weeks)
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004858 10037084 Prurigo nodularis LLT
    17.0 100000004858 10018123 Generalized pruritus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-005594-36 Sponsor Protocol Number: PHT/2014/107 Start Date*: 2015-12-15
    Sponsor Name:Portsmouth Hospitals NHS Trust
    Full Title: A Phase IV, Randomised, Double-Blind, Controlled, Parallel Group Trial to Evaluate the Effectiveness and Safety of Balneum Plus vs Emollient in the Treatment of Uraemic Pruritus in Haemodialysis Pa...
    Medical condition: Uraemic Pruritus
    Disease: Version SOC Term Classification Code Term Level
    18.1 10040785 - Skin and subcutaneous tissue disorders 10060875 Uraemic pruritus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-001581-10 Sponsor Protocol Number: TCP-101 Start Date*: 2014-07-22
    Sponsor Name:Tigercat Pharma, Inc.
    Full Title: A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose Finding and Efficacy Study of VPD-737 in the Treatment of Subjects with Chronic Pruritus
    Medical condition: Chronic pruritus
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: View results
    EudraCT Number: 2017-004210-25 Sponsor Protocol Number: MTI-106 Start Date*: 2018-06-04
    Sponsor Name:Menlo Therapeutics Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Pruritus in Adults With Prurigo Nodularis
    Medical condition: Pruritus in adults with prurigo nodularis (PN)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10037087 Pruritus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2017-004098-15 Sponsor Protocol Number: DS107G-04-UP1 Start Date*: 2018-01-30
    Sponsor Name:DS Biopharma
    Full Title: A Randomised, Double-blind, Placebo-controlled, Phase 2 Study to Assess the Efficacy and Safety of Orally Administered DS107 in a once daily dose of 2g in Haemodialysis Patients with Moderate to Se...
    Medical condition: Moderate to Severe Uremic Pruritus
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10060884 Uremic pruritus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Prematurely Ended) EE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-002526-25 Sponsor Protocol Number: EP-547-201 Start Date*: 2023-02-22
    Sponsor Name:Escient Pharmaceuticals, Inc.
    Full Title: Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP547 in Subjects with Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis
    Medical condition: Subjects with Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis
    Disease: Version SOC Term Classification Code Term Level
    24.1 10040785 - Skin and subcutaneous tissue disorders 10064190 Cholestatic pruritus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-000410-38 Sponsor Protocol Number: LP0066-1019 Start Date*: 2013-10-25
    Sponsor Name:LEO Pharma A/S
    Full Title: Topical Aprepitant in Prurigo Patients (iTAPP) An exploratory phase IIa trial with topically applied aprepitant in patients with prurigo
    Medical condition: Prurigo can present either with hyperkeratotic nodules as prurigo nodularis or without nodules as Prurigo simplex. The disease is characterised by intensely pruritic, lichenified, or excoriated pap...
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004858 10037084 Prurigo nodularis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-004211-40 Sponsor Protocol Number: MTI-107 Start Date*: 2018-06-07
    Sponsor Name:Menlo Therapeutics Inc.
    Full Title: An Open-Label Long-Term Safety Study of Serlopitant for the Treatment of Pruritus
    Medical condition: Pruritus associated with prurigo nodularis (PN), atopic dermatitis (AD), or psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10037087 Pruritus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended) PL (Completed)
    Trial results: View results
    EudraCT Number: 2013-002470-46 Sponsor Protocol Number: CIM003JG Start Date*: 2013-12-10
    Sponsor Name:Chugai Pharmaceutical Co. Ltd
    Full Title: A Phase II, randomized, double-blind, placebo-controlled, multiple-dose study to evaluate the safety, tolerability, and efficacy of CIM331 in atopic dermatitis patients who are inadequately control...
    Medical condition: Atopic dermatitis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 21:40:50 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA